CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

HOUSTON, July 15, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for the treatment of glioma brain tumors.

The release as fetched from its publisher. cnspharma.com ↗